$FTH

Cantor Fitzgerald reiterated an Overweight rating on Faeth Therapeutics (FTH) with price targets ranging from $40 to $70. The stock, trading at $16.83, has seen volatility, dropping 19% in the past week but up 66% over the past year. The firm hosted an investor dinner discussing trial results for sac-TMT and upcoming Phase 2 readout for PIKTOR. Analysts remain bullish, with earnings scheduled in 14 days.

Faeth Therapeutics (FTH) appointed Adam Schayowitz, Ph.D., as a Class III director on October 23, 2026. He received an option to purchase 25,000 shares, vesting over three years. Schayowitz is EVP and Head of R&D at Zymeworks and has prior oncology leadership roles at Pfizer. The term runs until the 2027 annual meeting.

Faeth Therapeutics, Inc. (FTH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 23, 2026, the Board of Directors (the “Board”) of Faeth Therapeutics, Inc. (the “Company”) increased the size o

BTIG maintained a Buy rating on Faeth Therapeutics with a $55 price target, suggesting a 226.8% upside from the last close. The firm highlighted the strong efficacy and safety of the PIKTOR program in treating endometrial and breast cancer, as well as its competitive advantage in tolerability.

Faeth Therapeutics (FTH) presented preclinical data at the European Society for Medical Oncology Congress 2026, showing its drug PIKTOR inhibited tumor growth in breast cancer mouse models. PIKTOR, a combination of serabelisib and sapanisertib, achieved complete tumor growth inhibition or regression when combined with fulvestrant and palbociclib. The company is conducting Phase 2 trials in endometrial and breast cancer, with data expected by year-end 2026 and 2027, respectively.

Faeth Therapeutics (FTH) granted options to buy 17,000 shares to three new hires. The options have an exercise price. Faeth is a clinical-stage biotech focused on cancer treatments, with PIKTOR as its lead program.

Faeth Therapeutics (FTH) will present preclinical data on PIKTOR, its experimental breast cancer drug, at the ESMO Congress 2026. The data compares PIKTOR's efficacy with gedatolisib in mouse models and includes combination therapy results. PIKTOR is being evaluated in Phase 1b/2 trial for HR+/HER2- breast cancer, with interim data expected in 2027.

William Blair initiated coverage on Faeth Therapeutics (NASDAQ:FTH) with an Outperform rating and a $66 price target. The company is developing PIKTOR, a combination therapy for cancers, with proof of concept expected later this year. Analysts have set targets ranging from $46 to $70, though some suggest the stock may be overvalued. Faeth has seen multiple positive analyst ratings and holds more cash than debt, providing financial runway for its clinical programs.

Sensei Biotherapeutics (FTH) presented data supporting its PIKTOR regimen, combining serabelisib and sapanisertib, ahead of an upcoming trial readout. The company reported improved progression-free survival in endometrial cancer patients and highlighted safety and dose-selection data. It also discussed potential market opportunities in breast and endometrial cancer, estimating a $5 billion and $1.5 billion annual market, respectively.

Faeth Therapeutics, Inc. (FTH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 11, 2026, the Board of Directors (the “Board”) of Faeth Therapeutics, Inc. (the “Company”) increased the size